Psoriasis Standardized Diagnosis and Treatment Center and real-world big data collection platform project launched in Beijing.

Introduction: The 3rd Northern University Summit Forum on Sustainable and Rapid Development of Dermatology was successfully held to explore the national collaborative path of the National Center for Clinical Medicine of Skin and Immunological Diseases.
August 29, 2020, the 3rd North University Summit Forum on Sustainable and Rapid Development of Dermatology was held in Beijing, which was also the first National Dermatology Development Strategy Seminar held since the establishment of the National Center for Clinical Medicine of Skin and Immunological Diseases, based on the First Hospital of Peking University.
The National Center for Clinical Medicine of Skin and Immunological Diseases (based on Peking University First Hospital, "Center"), was established by the Ministry of Science and Technology, the National Health And Wellness Commission, the Central Military Commission Logistics Support Department and the State Drug Administration in May 2019.
Center's focus is on conducting basic and clinical research with clinical applications as the goal through national collaboration, emphasizing the transformational application of innovative results, ultimately improving the level of diagnosis and treatment of skin diseases, and promoting the quality of clinical treatment throughout the country.
Due to the impact of the outbreak, this meeting used 15 cities real-time connected network meeting form, the main venue is set in Beijing, dermatologists across the country can choose a branch of the meeting, can also arrange their own on the network to listen to the meeting.
statistics, nearly a thousand hospitals attended, the number of participants 10,718.
meeting received broad support from leaders from all walks of life.
Ms. Guo Yanhong, Deputy Director of the Department of Social Development Science and Technology of the Ministry of Science and Technology, and Ms. Guo Yanhong, Director of the Medical Administration of the National Health And Human Rights Commission, addressed the meeting in person, Mao Zhenbin, First-level Inspector of the Science, Technology and International Cooperation Department of the State Drug Administration, and Director of the Medical Department of Peking University, Executive Vice President of Peking University Professor Zhan Qimin, Deputy Secretary of the Party Committee of Peking University, Peking University Medical Department, Professor Liu Yucun, Deputy Director of The Department of Medicine of Peking University, Professor Zhang Ning, Director of the Department of Scientific Research of Peking University, Professor Pan Yisheng, Secretary of the Party Committee of Peking University First Hospital, Professor Liu Xinmin, Dean, and Professor Yang Li, Vice Dean of Scientific Research, sent congratulatory messages via video message.
conference, The Executive Deputy Director of the Department of Medicine of Peking University and Director of the National Center for Clinical Medicine of Obstetrics and Gynecology, Dr. Qiao Jie, delivered a keynote speech on the topic of "Exploring New Models of Discipline Development with the Platform of the National Clinical Medical Research Center".
, the "Joint Laboratory and Shared Service Platform for Dermatology Literature Information" jointly established by the Center and the Medical Library of Peking University was officially listed at the conference.
psoriasis is a common and incurable disease in dermatology.
Center to psoriasis as the starting point, in this conference officially launched the "psoriasis standardized diagnosis and treatment center and psoriasis diagnosis and treatment of real-world big data collection platform" project (the "project").
as the center launched the first national collaborative project, hoping to explore the national multi-center collaboration win-win clinical research model, while improving the overall level of psoriasis diagnosis and treatment in China.
project plans to cover 100 hospitals by the end of 2020.
in the early pilot work, 93 hospitals have successfully applied to join the "psoriasis standardized diagnosis and treatment center" construction.
China Psoriasis Standardized Diagnosis and Treatment Center was officially established as the central responsibility, will continue to innovate to explore new paths of clinical medical research and transformation, such as to improve the efficiency of clinical research for the purpose of establishing an ethical alliance;
Center also plans to actively promote the joint development of medical enterprises: from incubation research to pre-market, post-market research, to popularize, try the "research-transformation-promotion" new model, the establishment of clinical research and development of new modality.
this meeting, as a joint demonstration project of medical enterprises, also held a special meeting - the second Novardic Skin Immunity Summit Forum.
Pico "old difficulties" ushered in a new era, become the center of "pathfesting" breakthrough " to choose psoriasis as the National Center for Clinical Medicine of Skin and Immunological Diseases work of the entry point is its history and historical factors.
," said Professor Li Ruyu.
, psoriasis is recognized as a "big problem" disease in the field of pico.
as a lifelong, recurring, systemic disease, psoriasis can not be cured.
long course of the disease, and may be accompanied by many serious diseases, such as diabetes, heart disease, depression, etc. , but also to the patient's physical and mental double blow.
, on the other hand, with the continuous emergence of innovative drugs in recent years, "manage" psoriasis, so that patients continue to have normal skin and even achieve "skin damage" has become an achievable therapeutic goal.
"weapons and ammunition" are in place, but whether doctors will use, use, and use them skillfully is a question.
, " says Prof Li.
to the biologics in innovative drugs as an example, in 2019, a number of white methicillin inhibitors entered China, representing the choice of drug use in China has been synchronized with developed countries.
in practice, however, the use of such drugs is mostly concentrated in large hospitals in large cities in the first and second tiers, and the cognitive and experience of many primary dermatologists is still limited.
" in the face of a large number of psoriasis patients and the rapid development of medicine, we see the hopeful side of psoriasis treatment, but also see the level of progress in diagnosis and treatment space, so choose this field of disease as an entry point, for the center's longer-term construction to sum up experience, set an industry benchmark.
, " says Prof Li.
to build a "model" of diagnosis and treatment, "intellectual" local data, to enhance the level of psoriasis diagnosis and treatment in China according to the current status and experience of psoriasis diagnosis and treatment, the center will be implemented from the following three aspects to ensure the smooth landing of the project: 1.Explore the promotion of psoriasis standardized diagnosis and treatment process: the project developed a strict "psoriasis standardized diagnosis and treatment center application process", hospitals need to meet a number of declaration conditions to apply, including the need for hospitals to have an independent dermatology clinic, psoriasis patients monthly outpatient volume of more than 100 people, biological agent use experience, can support big data entry and transmission.
the National Center for Clinical Medicine for Skin and Immunological Diseases will also build support and assessment from both "hardware" (hospital construction) and "software" (diagnosis and treatment capacity).
2.Establish a real-world clinical database of psoriasis cases in China: Under the framework of the project, several psoriasis standardized treatment centers collaborate to collect real-world big data for psoriasis diagnosis and treatment, and jointly establish China's first clinical big data research platform open to the outside world under the premise of ensuring data security.
the management methods of psoriasis standardized diagnosis and treatment centers, all project participants have the right to apply data to initiate and conduct clinical research.
both data producers and data users, win-win development, and ultimately achieve "local data for the benefit of local patients."
3.To carry out consultation and multi-dimensional teaching of difficult diseases: to achieve the standardization of different psoriasis diagnosis and treatment centers between the exchange of resources, experience sharing.
set a regional benchmark effect to improve the level of doctor's diagnosis and treatment.
Professor Li Wei, Executive Deputy Director of the National Center for Clinical Medicine of Skin and Immunological Diseases, said: "The establishment of the real-world clinical database of psoriasis is a very meaningful attempt, on the one hand, it will promote the construction of the hardware and software and standard system of clinical research in major hospitals across the country, on the other hand, it will vigorously promote the national psoriasis diagnosis and treatment of water quality, in addition to the project will serve as a template for other key diseases clinical research, will affect the development of the field of dermatology in all aspects."
" in the field of innovative treatment of psoriasis has a large amount of research and development investment Novarce Pharmaceuticals has also given strong support to the project, fully reflects the National Center's core work strategy, that is, the active introduction of high-quality industry cooperation resources to promote the overall development of all kinds of cooperation to ultimately guide the rapid development of the industry as a whole.
.